A Study Combining Personalized Neoantigen-based Dendritic Cell Vaccine With Microwave Ablation for the Treatment of Hepatocellular Carcinoma

Inclusion criteria

• Histologically confirmed patients with primary hepatocellular carcinoma, HKLC Stage IIa.
• Age is greater than 18 years old, male or female.
• The tumor size is 3cm-5cm, and the lesions are <3.
• ECOG score < 2, Child-Pugh classification A or B.
• The participants freely sign informed consent;

Exclusion criteria

• Pregnant or breast-feeding; psychiatric problems, addiction, or any other disorder that prevented informed consent;
• Portal vein thrombosis or extrahepatic metastases;
• White blood cell count <2 x 10e9/L, platelet count <40 x 10e9/L, serum creatinine >110 mol/L, aspartate aminotransferase >3 times upper limit, serum bilirubin > 2.5 times upper limit, prothrombin time> 19 seconds.
• Active uncontrolled infection;
• Concurrent systemic corticosteroid treatment
• Primary immunodeficiency or systemic autoimmune disease; being treated with immunosuppressive drugs for other diseases;
• Clinically significant ischemic heart disease or cardiac failure;
• The investigator believes that there are other reasons that are not suitable for inclusion.